Erik I. Tucker

Chief Executive Officer
Aronora, Inc.

Presentation(s):

• PB0553 - The antithrombotic protein C activator thrombin mutant W215A/E217A (AB002, E-WE) is slowly inhibited by the endogenous thrombin inhibitors antithrombin, protein C inhibitor, and heparin cofactor II

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• VPB0583 - Procoagulant Properties of Titanium and Titanium Nitride

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• OC 65.3 - A Phase 2 Trial Evaluating the Safety and Antithrombotic Efficacy of AB002, a First-in-class Protein C Activator in End-stage Renal Disease Patients on Heparin-free Hemodialysis

  Tuesday, July 12, 2022
  3:15 PM – 3:30 PM